The latest London South East Webinar takes place on July 6. Come and hear CEO’s from Orosur Mining, Caledonia Mining, Glantus Holdings and Tekcapital speak. Please register here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAmryt Pharma Share News (AMYT)

Share Price Information for Amryt Pharma (AMYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 167.50
Bid: 165.00
Ask: 170.00
Change: 0.00 (0.00%)
Spread: 5.00 (3.03%)
Open: 167.50
High: 167.50
Low: 167.50
Yest. Close: 167.50
AMYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Amryt gets FDA fast track for Oleogel-S10

(Sharecast News) - Biopharmaceutical company Amryt Pharma announced on Tuesday that the US Food and Drug Administration (FDA) has designated the investigation of 'AP101' - Oleogel-S10 - for the treatment of epidermolysis bullosa (EB) as a 'Fast Track' development programme.

1 Oct 19 15:08

Amryt Pharma Loss Widens On Aegerion Deal Costs; Lojuxta Revenue Rises

Amryt Pharma Loss Widens On Aegerion Deal Costs; Lojuxta Revenue Rises

30 Sep 19 18:49

Amryt Pharma Completes Combination With Aegerion Pharmaceuticals

Amryt Pharma Completes Combination With Aegerion Pharmaceuticals

25 Sep 19 12:24

Amryt Pharma Shares Temporarily Suspended On Aegerion Buy

Amryt Pharma Shares Temporarily Suspended On Aegerion Buy

24 Sep 19 15:00

Amryt Pharma Agrees To All-Paper Acquisition Of Aegerion (ALLISS)

LONDON (Alliance News) - Amryt Pharma PLC on Tuesday said it has agreed the all-paper acquisition of Aegerion Pharmaceuticals, a subsidiary of Novelion Therapeutics Inc, and intends to raise USD60

21 May 19 12:35

Amryt Pharma Loss Narrows On Revenue From Cholesterol Drug Lojuxta

LONDON (Alliance News) - Amryt Pharma PLC on Wednesday said its annual loss narrowed as a result of increased revenue from its drug Lojuxta.The company's pretax loss shrank to EUR25.7

17 Apr 19 11:17

Amryt gets approval to extend EASE trial to infants and children

(Sharecast News) - Orphan drug company Amryt Pharma updated the market on its phase 3 'EASE' trial for AP101 as a potential treatment for epidermolysis bullosa (EB) on Thursday, reporting that following an assessment by the trial's independent data monitoring committee, it could now enrol infants and children with EB between the ages of 21 days to four years in the trial.

28 Feb 19 14:39

Redx Pharma Issues 750,000 Shares In Order To Reduce Headquarter Lease (ALLISS)

LONDON (Alliance News) - Biotechnology firm Redx Pharma PLC on Thursday said it has changed the lease agreement at its Alderley Park headquarters in Cheshire, England, reducing the amount of will

28 Feb 19 14:06

Amryt Pharma Now Permitted To Enrol Children Under Four In Ease Trial

LONDON (Alliance News) - Amryt Pharma PLC on Thursday said it now has permission to enrol infants and children under four years old in its ongoing phase three Ease trial of AP101 in the Ease will

28 Feb 19 12:12

Amryt Pharma Reports Positive Results For Gene Therapy In Skin Disease

LONDON (Alliance News) - Amryt Pharma PLC on Monday reported positive results from two pre-clinical studies of its novel non-viral gene therapy for recessive dystrophic epidermolysis company said

7 Jan 19 09:41

Amryt Pharma given go-ahead to continue Phase III EASE trial

(Sharecast News) - Revenue-generating orphan drug company Amryt Pharma announced the results of an unblinded interim efficacy analysis on its pivotal Phase III EASE trial for AP101 as a potential treatment for Epidermolysis Bullosa (EB) on Friday.

4 Jan 19 14:41

Committee Recommends Adding More Patients To Amryt Pharma's Ease Trial

LONDON (Alliance News) - Amryt Pharma PLC on Friday said an independent data monitoring committee has recommended adding more patients to its phase three Ease trial of epidermolysis bullosa drug a

4 Jan 19 13:32

Amryt Pharma flags slight delay to EASE trial data

(Sharecast News) - Orphan drug company Amryt Pharma updated the market on the global AP101 EASE Phase III clinical trial being conducted in patients with Epidermolysis Bullosa (EB) on Wednesday, reporting that the independent data monitoring committee was scheduled to meet on 21 December to review the EASE unblinded interim efficacy analysis results.

19 Dec 18 11:22

Amryt Pharma scores €8.4m grant from Irish government

(Sharecast News) - Amryt Pharma announced on Monday that it has secured am €8.4m grant from the Irish Government for three years of development of its AP103 gene therapy platform.

10 Dec 18 16:39

Amryt Pharma Secures Irish Government Grant To Develop AP103 Platform

LONDON (Alliance News) - Amryt Pharma PLC on Monday said it has secured grant funding of EUR8.4 million over three years to develop its AP103 gene therapy platform.Amryt shares were trading

10 Dec 18 12:12

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.